Reckitt grows Q2 sales
This article was originally published in The Rose Sheet
Executive Summary
Health and personal care division sales rebounded in the second quarter, growing 10% to £546 mil. ($845.7 mil.), Reckitt Benckiser reports July 26. The sector, which accounts for 26% of the company's net sales, rallied in the April-June period, with growth in emerging markets offsetting a lackluster performance in Europe, the U.K.-based firm said. The Veet depilatory and Clearasil acne treatment lines performed well in North America. A Societe Generale analyst note said organic growth in health and personal care "recovered as we had hoped and this division has regained its status as the group's main growth driver." Firm's net sales grew 6% for the quarter to £2.06 bil. ($3.19 bil.)
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.